Gland Pharma Ltd Technical Momentum Shifts Amid Mixed Indicator Signals

Technical Trend Overview and Price Movement

As of 13 Feb 2026, Gland Pharma’s stock price closed at ₹1,816.00, down from the previous close of ₹1,866.05. The intraday range saw a high of ₹1,853.90 and a low of ₹1,811.15, indicating some volatility within the session. The stock remains well below its 52-week high of ₹2,130.00 but comfortably above its 52-week low of ₹1,200.00, suggesting a broad trading range over the past year.

The recent technical trend has shifted from sideways to mildly bearish, primarily driven by daily moving averages signalling a downturn. This shift is significant given the stock’s prior sideways consolidation, which often precedes directional moves. The daily moving averages, which smooth out price fluctuations, have deteriorated, indicating short-term selling pressure.

MACD and Momentum Indicators

The Moving Average Convergence Divergence (MACD) indicator presents a mixed scenario. On a weekly basis, the MACD remains mildly bullish, suggesting some underlying positive momentum in the medium term. However, the monthly MACD has turned mildly bearish, signalling that longer-term momentum is weakening. This divergence between weekly and monthly MACD readings highlights a transitional phase for the stock’s momentum, where short-term optimism is tempered by longer-term caution.

Complementing this, the Know Sure Thing (KST) indicator shows bearishness on the weekly chart but bullishness on the monthly chart. This further emphasises the conflicting signals between short-term and long-term momentum, underscoring the importance of a cautious approach for investors looking at different time horizons.

RSI and Bollinger Bands Analysis

The Relative Strength Index (RSI) on both weekly and monthly timeframes currently offers no clear signal, hovering in neutral territory. This suggests that the stock is neither overbought nor oversold, leaving room for either a rebound or further decline depending on upcoming market catalysts.

Bollinger Bands, which measure volatility and potential price breakouts, are mildly bullish on both weekly and monthly charts. This indicates that despite the recent price dip, the stock’s volatility profile supports a potential upward move or at least a stabilisation in price levels. The bands’ mild bullishness may reflect a consolidation phase where price compression could precede a breakout.

On-Balance Volume and Dow Theory Signals

The On-Balance Volume (OBV) indicator, which tracks buying and selling pressure, shows no clear trend on the weekly chart but is mildly bullish on the monthly timeframe. This suggests that while short-term volume flows are indecisive, longer-term accumulation may be occurring, providing some support to the stock price.

Dow Theory assessments align with this mixed outlook. The weekly chart shows no definitive trend, whereas the monthly chart is mildly bullish. This indicates that the broader market forces may still favour Gland Pharma over the medium term, despite short-term fluctuations.

Comparative Returns and Market Context

Examining Gland Pharma’s returns relative to the Sensex provides additional context. Over the past week, the stock declined by 1.83%, underperforming the Sensex’s 0.43% gain. However, over the last month, Gland Pharma outperformed with a 6.62% return compared to the Sensex’s slight decline of 0.24%. Year-to-date, the stock has gained 5.44%, while the Sensex has fallen 1.81%, and over the past year, Gland Pharma’s 23.86% return significantly outpaces the Sensex’s 9.85%.

Longer-term returns show a mixed picture: a 3-year return of 38.35% closely matches the Sensex’s 37.89%, but over five years, Gland Pharma has underperformed with a negative 17.05% return against the Sensex’s robust 62.34%. This divergence highlights the stock’s volatility and sector-specific challenges over extended periods.

Mojo Score and Analyst Ratings

MarketsMOJO assigns Gland Pharma a Mojo Score of 50.0 with a current Mojo Grade of Hold, upgraded from Sell on 2 Feb 2026. This upgrade reflects an improvement in the company’s technical and fundamental outlook, though the Hold rating suggests investors should remain cautious. The Market Cap Grade stands at 3, indicating a mid-tier market capitalisation relative to peers in the Pharmaceuticals & Biotechnology sector.

The downgrade in daily moving averages and the mildly bearish technical trend contrast with the more positive monthly indicators, reinforcing the Hold stance. Investors should weigh these mixed signals carefully, considering both short-term risks and medium-term opportunities.

Investor Takeaways and Outlook

Gland Pharma’s technical indicators reveal a complex momentum landscape. The mildly bearish daily moving averages and weekly KST bearishness caution investors about near-term downside risks. Conversely, the mildly bullish monthly MACD, Bollinger Bands, OBV, and Dow Theory signals suggest that the stock retains underlying strength over longer horizons.

Given the neutral RSI readings and mixed volume trends, the stock appears to be in a consolidation phase, where price action could pivot sharply in either direction depending on sector developments, regulatory news, or broader market sentiment. Investors should monitor key support levels near ₹1,800 and resistance around ₹1,850 to ₹1,900 for signs of trend confirmation.

Comparatively, Gland Pharma’s recent outperformance against the Sensex on monthly and yearly bases indicates resilience within the Pharmaceuticals & Biotechnology sector, though the five-year underperformance signals caution for long-term holders. The upgrade from Sell to Hold by MarketsMOJO reflects this balanced view, recommending a watchful stance rather than aggressive accumulation.

In summary, Gland Pharma Ltd’s technical momentum shift underscores the importance of a nuanced approach. Short-term traders may find opportunities in the volatility, while long-term investors should consider the mixed signals and sector fundamentals before adjusting their positions.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →